ThaiPR.NET https://www.thaipr.net/location/gaithersburg-md-and-pune-india Press Release Distribution Center of Thailand Fri, 24 Apr 2026 17:45:02 +0700 hourly 1 https://wordpress.org/?v=6.1.1 <![CDATA[Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax’ COVID-19 Vaccine in Thailand]]> https://www.thaipr.net/en/health_en/3178894 Mon, 11 Apr 2022 08:00:00 +0700 health_en https://www.thaipr.net/en/health_en/3178894 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced that the Thailand Food and Drug Administration (Thai FDA) has granted emergency use authorization (EUA) for Novavax’ protein-based vaccine for active immunization […]

The post Novavax and Serum Institute of India Receive Emergency Use Authorization for Novavax’ COVID-19 Vaccine in Thailand appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents ≥12 to <18 in India]]> https://www.thaipr.net/en/general_en/3171281 Wed, 23 Mar 2022 09:45:00 +0700 general_en https://www.thaipr.net/en/general_en/3171281 First authorization of Novavax’ COVID-19 vaccine in adolescent population received Covovax™ (SARS-CoV-2 rS Protein (COVID-19) recombinant spike protein Nanoparticle Vaccine) is the first protein-based COVID-19 vaccine authorized for adolescents ≥12 to <18 in India Authorization highlights immunogenicity and reassuring safety profile of Covovax in Phase 2/3 study of Indian adolescents aged ≥12 to <18 and data from […]

The post Novavax and Serum Institute of India Announce First Emergency Use Authorization of Novavax’ COVID-19 Vaccine in Adolescents ≥12 to <18 in India appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India]]> https://www.thaipr.net/en/health_en/3139807 Wed, 29 Dec 2021 08:50:00 +0700 health_en https://www.thaipr.net/en/health_en/3139807 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced that the Drugs Controller General of India (DCGI) has granted emergency use authorization (EUA) for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine […]

The post Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in India appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine]]> https://www.thaipr.net/en/health_en/3135748 Mon, 20 Dec 2021 08:15:00 +0700 health_en https://www.thaipr.net/en/health_en/3135748 First EUL granted by WHO for a protein-based COVID-19 vaccine EUL vaccine manufactured and marketed by SII as COVOVAX™ WHO EUL for Nuvaxovid™ currently under assessment; will be completed following European Medicines Agency (EMA) review Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute […]

The post Novavax and Serum Institute of India Announce World Health Organization Grants Emergency Use Listing for NVX-CoV2373 COVID-19 Vaccine appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines]]> https://www.thaipr.net/en/general_en/3123333 Thu, 18 Nov 2021 09:15:00 +0700 general_en https://www.thaipr.net/en/general_en/3123333 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced that the Philippine Food and Drug Administration (FDA) has granted emergency use authorization (EUA) for Novavax’ recombinant nanoparticle protein-based COVID-19 vaccine with […]

The post Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in the Philippines appeared first on ThaiPR.NET.

]]> <![CDATA[Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia]]> https://www.thaipr.net/en/health_en/3116421 Tue, 02 Nov 2021 09:25:00 +0700 health_en https://www.thaipr.net/en/health_en/3116421 Novavax, Inc. (Nasdaq: NVAX), a biotechnology company dedicated to developing and commercializing next-generation vaccines for serious infectious diseases, and Serum Institute of India Pvt. Ltd. (SII), the world’s largest vaccine manufacturer by volume, today announced that the National Agency of Drug and Food Control of the Republic of Indonesia, or Badan Peng was Obat dan Makanan […]

The post Novavax and Serum Institute of India Receive Emergency Use Authorization for COVID-19 Vaccine in Indonesia appeared first on ThaiPR.NET.

]]>